InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,699.94
(
-0.17%
)
US TECH 100
19,261.20
(
-0.09%
)
Dow Jones
42,011.59
(
-0.44%
)
Brent Oil
77.55
(
-0.33%
)
Bitcoin
61,200.54
(
0.74%
)
Post# of 253272
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

caravon

Send PM Follow Ignore
Followers 13
Posts 1058
Boards Moderated 0
Alias Born 02/21/2007

caravon

Re: poorgradstudent post# 160466

Monday, 04/29/2013 6:36:18 PM

Monday, April 29, 2013 6:36:18 PM

Post# of 253272
Novartis is running 5 Ph2 c-MET inhibitor INC280 clinical trials.
All trials are open label with ~60 pts each covering both Asia and EU/US population.

NVS is a good company. It knows how to run clinical trials.

ARQL management is too busy rewarding themselves with bonuses for their incompetence and greed.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up